title: Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
abstract: Dendritic cells (DCs) are potent antigen presenting cells and represent attractive candidates for use in novel immunotherapies for patients with renal cell carcinoma (RCC), a disease that has proven refractory to conventional treatment modalities, such as chemotherapy and radiotherapy. Given the perceived need to augment antitumor type-1 immunity (TC1 and Th1) as a therapeutic end point, and the known functional plasticity of DC populations that may display heterogeneous capacity to promote T-cell responses, we sought to identify a preferred DC preparation with this capacity. We compared 2 different preparations of monocyte-derived DC using interferon-alpha (IFN-alpha) (IFN-DC and alphaDC1) with classic DCs "matured" (mDCs) using interleukin-1beta/interleukin-6/tumor necrosis factor-alpha/prostaglandin E2, for their ability to promote autologous TC1 antitumor responses from RCC patients in vitro. IFN-alpha-conditioned DC promoted significantly higher numbers of RCC-specific CD8+ T cells exhibiting a cytotoxic phenotype after in vitro stimulation (IVS) than cytokine cocktail-mDCs. Furthermore, IVS using IFN-DCs was able to diminish regulatory-type T cells among CD4+ T-cell responder populations versus IVS using conventional mDC-based vaccines. These data emphasize an important role for IFN-alpha in modulating the immunologic functions of DCs toward a polarized DC1-type capable of coordinately promoting TH1-type and TC1-type T-cell mediated immunity and supports the translational development of patient-derived IFN-alpha-conditioned DC for use in novel immunotherapies for patients with RCC, and in whom, endogenous tumor-specific TC1 effector cells may be dysfunctional, anergic, or prone to undergo apoptosis.
authors.affiliation: Department of Biomedical Sciences, University of Foggia, Foggia, Italy.
authors.forename: Margherita
authors.initials: M
authors.lastname: Gigante
authors.forename: Maja
authors.initials: M
authors.lastname: Mandic
authors.forename: Amy K
authors.initials: AK
authors.lastname: Wesa
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Cavalcanti
authors.forename: Michele
authors.initials: M
authors.lastname: Dambrosio
authors.forename: Vito
authors.initials: V
authors.lastname: Mancini
authors.forename: Michele
authors.initials: M
authors.lastname: Battaglia
authors.forename: Loreto
authors.initials: L
authors.lastname: Gesualdo
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Storkus
authors.forename: Elena
authors.initials: E
authors.lastname: Ranieri
mesh_terms: D002292:Carcinoma, Renal Cell / Q000097:blood / Q000276:immunology* / Q000473:pathology; D002450:Cell Communication; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D016207:Cytokines / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007156:Immunologic Memory; D016233:Immunotherapy, Active; D007370:Interferon Type I / Q000276:immunology / Q000494:pharmacology; D016898:Interferon-alpha / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D007371:Interferon-gamma / Q000276:immunology; D007680:Kidney Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D011994:Recombinant Proteins; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology*
chemical_list: D016207:Cytokines; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007371:Interferon-gamma